Coherus Biosciences Inc (NASDAQ:CHRS) price on Wednesday, April 30, rose 3.04% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.03.
A look at the stock’s price movement, the close in the last trading session was $1.00, moving within a range at $0.95 and $1.05. The beta value (5-Year monthly) was 1.011 while the PE ratio in trailing twelve months stood at 5.91. Turning to its 52-week performance, $2.43 and $0.66 were the 52-week high and 52-week low respectively. Overall, CHRS moved 27.63% over the past month.
Coherus Biosciences Inc’s market cap currently stands at around $119.37 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-09.
Analysts have a consensus estimate of 60.96M for the company’s revenue for the quarter, with a low and high estimate of 52.36M and 71.5M respectively. The average forecast suggests down to a -20.89% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 99.92M, representing a -62.57% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CHRS is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 3 recommend CHRS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CHRS’s current price about 8.43% and 5.76% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 53.81, while 7-day volatility ratio is 8.16% and 10.69% in the 30-day chart. Further, Coherus Biosciences Inc (CHRS) has a beta value of 1.02, and an average true range (ATR) of 0.09. Analysts have given the company’s stock an average 52-week price target of $3.525, forecast between a low of $1.05 and high of $6. Looking at the price targets, the low is -1.94% off current price level while to achieve the yearly target high, price needs to move -482.52%. Nonetheless, investors will most likely welcome a -242.23% jump to $3.525 which is the analysts’ median price.
If we refocus on Coherus Biosciences Inc (NASDAQ:CHRS), historical trading data shows that trading volumes averaged 1.72 over the past 10 days and 1.81 million over the past 3 months. The company’s latest data on shares outstanding shows there are 115.61 million shares.
The 3.98% of Coherus Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 54.09% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 33.03 million on 2025-04-15, giving us a short ratio of 16.41. The data shows that as of 2025-04-15 short interest in Coherus Biosciences Inc (CHRS) stood at 3324.0002000000004 of shares outstanding, with shares short rising to 32.55 million registered in 2025-03-14. Current price change has pushed the stock -25.36% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CHRS stock continues to rise going into the next quarter.
